BennuBio, Inc. 609 Broadway Blvd NE. Albuquerque, NM 87102 505-246-6901 www.bennubio.com [email protected]Page 1 | 1 BennuBio Inc. Company Overview: BennuBio Inc. provides revolutionary cellular and particle diagnostic instrumentation for biomedical diagnostics, pharmaceutical discovery, and industrial process monitoring. Using patented parallel acoustic particle positioning and analysis technology, our instruments transcend critical limitations for flow-based cell, cellular system, and large particle analysis instrumentation. Our instruments offer clear advantages by enabling total sample recovery, larger particle size, high analytical rates, and large volume sample analysis. Product Overview: Our initial product, the Velocyt, is named to indicate the dramatically increased speed and efficiency that it provides as compared to a typical flow-based particle analyzer, which are also often called flow cytometers. The Velocyt will match existing instruments in terms of optical parameters and sensitivity (e.g. 1 – 4 lasers, 4 – 16 colors collected, and the ability to detect ~500 fluorophores), but our systems will provide user adjustable flow rates up to 10 milliliters per minute and analysis rates of up to 200,000 events per second, which is ten-fold higher than the 20,000 per second typically achieved by most current flow analyzers. Moreover, our system will use less consumables, provide total sample recovery, and analyze particles that are up to a millimeter in diameter. These advantages provide value to customers in the form of: 1. CONFIDENCE in their results due to our high analytical rates, sensitivity, and total sample recovery, ensuring a level of statistical confidence not heretofore possible. 2. PRODUCTIVITY in their workflow as they will not have to centrifuge or wash their samples, which will provide more cost effective and faster processes. 3. FLEXIBILITY of approach, made possible by the myriad of sample types and volumes, the large range cell/particle sizes, and total sample recovery. Our system will be similar in cost to current systems but offer essentially 10-fold the analytical capability. This is our core platform from which we will offer a family of instruments to address the biomedical research, drug discovery, process monitoring, and clinical diagnostic markets. Market Opportunity: The worldwide global flow-based particle analysis (flow cytometry) market is expected to reach $8 billion by 2025 and is currently nearly $4 billion in size. Much of the market growth is expected to be in small size high throughput flow cytometers. This matches our target markets well. While these large markets are of interest, they do not even fully capture emerging markets that our instruments should be able to address, which include process monitoring of pharmaceuticals and of dairy products, as such our products are addressing a market that is tens of billions of dollars in size. Management Team: Our leadership team, in aggregate, has greater than 80 years of experience in cellular analysis, particle analysis, flow cytometry, instrumentation development, and leadership of technology companies in these areas. Our CEO is Steven Graves who has 25 years of experience in cellular and particle analysis instrumentation is derived from active research by Graves. Our CTO is Travis Woods, with 17 years of experience leading instrument development. Our CSO is James Freyer who has 40 years of experience in flow cytometry. Our CFO is Stephen McKernan, the former CEO of University of New Mexico Hospitals. Our board includes Terry Dunlay (the former CEO of Intellicyt), Waneta Tuttle (Managing Partner of Tramway Venture Partners, David Blivin of the Cottonwood Technology Fund, and Sally Corning of Sun Mountain Capital. This team provides us leadership in all areas of our business.
Transcript
BennuBio, Inc. 609 Broadway Blvd NE. Albuquerque, NM 87102 505-246-6901 www.bennubio.com [email protected]
P a g e 1 | 1
BennuBio Inc.
Company Overview: BennuBio Inc. provides revolutionary cellular and particle diagnostic instrumentation for biomedical diagnostics, pharmaceutical discovery, and industrial process monitoring. Using patented parallel acoustic particle positioning and analysis technology, our instruments transcend critical limitations for flow-based cell, cellular system, and large particle analysis instrumentation. Our instruments offer clear advantages by enabling total sample recovery, larger particle size, high analytical rates, and large volume sample analysis.
Product Overview: Our initial product, the Velocyt, is named to indicate the dramatically increased speed and efficiency that it provides as compared to a typical flow-based particle analyzer, which are also often called flow cytometers. The Velocyt will match existing instruments in terms of optical parameters and sensitivity (e.g. 1 – 4 lasers, 4 – 16 colors collected, and the ability to detect ~500 fluorophores), but our systems will provide user adjustable flow rates up to 10 milliliters per minute and analysis rates of up to 200,000 events per second, which is ten-fold higher than the 20,000 per second typically achieved by most current flow analyzers. Moreover, our system will use less consumables, provide total sample recovery, and analyze particles that are up to a millimeter in diameter. These advantages provide value to customers in the form of:
1. CONFIDENCE in their results due to our high analytical rates, sensitivity, and total sample recovery, ensuring a level of statistical confidence not heretofore possible.
2. PRODUCTIVITY in their workflow as they will not have to centrifuge or wash their samples, which will provide more cost effective and faster processes.
3. FLEXIBILITY of approach, made possible by the myriad of sample types and volumes, the large range cell/particle sizes, and total sample recovery.
Our system will be similar in cost to current systems but offer essentially 10-fold the analytical capability. This is our core platform from which we will offer a family of instruments to address the biomedical research, drug discovery, process monitoring, and clinical diagnostic markets.
Market Opportunity: The worldwide global flow-based particle analysis (flow cytometry) market is expected to reach $8 billion by 2025 and is currently nearly $4 billion in size. Much of the market growth is expected to be in small size high throughput flow cytometers. This matches our target markets well. While these large markets are of interest, they do not even fully capture emerging markets that our instruments should be able to address, which include process monitoring of pharmaceuticals and of dairy products, as such our products are addressing a market that is tens of billions of dollars in size.
Management Team: Our leadership team, in aggregate, has greater than 80 years of experience in cellular analysis, particle analysis, flow cytometry, instrumentation development, and leadership of technology companies in these areas. Our CEO is Steven Graves who has 25 years of experience in cellular and particle analysis instrumentation is derived from active research by Graves. Our CTO is Travis Woods, with 17 years of experience leading instrument development. Our CSO is James Freyer who has 40 years of experience in flow cytometry. Our CFO is Stephen McKernan, the former CEO of University of New Mexico Hospitals. Our board includes Terry Dunlay (the former CEO of Intellicyt), Waneta Tuttle (Managing Partner of Tramway Venture Partners, David Blivin of the Cottonwood Technology Fund, and Sally Corning of Sun Mountain Capital. This team provides us leadership in all areas of our business.
ElectroSonix, LC ◆ 1438 N Camino Villa Bonita, Tucson, AZ 85715 [email protected] ◆ 520-345-0859 ◆ www.electrosonix.net
ElectroSonix Fact Sheet 2019
Established: 2016 Employees: 4
Medical Device company
Milestones Founded February 2016
NIH Phase I SBIR September 2018
First employees January 2019
Imaging device FDA December 2021 submission
Ablation Device FDA December 2022 submission
Mission & Vision
ElectroSonix is developing noninvasive, high resolution cardiac imaging technologies that will benefit millions of patients with abnormal heart rhythms.
o US 8,057,390 High-resolution mapping of bio-electric fields
o US 8,427,906 Acoustic sensor utilizing acoustoelectric effect
• 3 filed PCT patents
Advantages Orders of magnitude improvement in imaging speed and accuracy over competition.
Products
We are building real-time, high-resolution imaging of electrical signals in the heart for feedback during ablation therapy. With faster and more accurate electrical mapping, this will reduce the number of ablations per procedure, procedure time, return procedures, as well as serious complications.
Russ Witte, PhD Founder & CSO Assoc. Professor, Medical Imaging,
Optical Sciences & Biomedical
Engineering, UA
Sonia Vohnout COO & VP
Entrepreneur, business
development, systems engineering, project management
Scientific Advisors Aiden Abidov, MD Benigno Decena, MD John Michels, MD Talal Moukabary, MD Matt O’Donnell, PhD
Advisory Board Jim Cantrell, CEO Vector Launch Marie Wesselhoft, CEO MSDx Mack Consigny, PhD Tech Launch Arizona
Emagine Solutions Technology 9040 S. Rita Road, Suite 1270 | Tucson, AZ 85747 Vistascan.co | [email protected]
Summary: Emagine Solutions Technology is a mobile healthcare company. Our VistaScan software shrinks a cart ultrasound machine into a regular cell phone so doctors can diagnose patients faster at a fraction of the cost. Product Overview:
VistaScan is mobile ultrasound technology that works in the palm of a doctor’s hand and is 10x less expensive than a cart-based ultrasound system, the current industry standard. The platform is available as a software as a service with the option to purchase accessories, including 3rd party probes. VistaScan utilizes four provisionally patented imaging features that make it faster and easier to scan and diagnose patients in time-sensitive patient care situations.
There currently over 20 clinicians waiting to beta test VistaScan. Main customer segments are emergency physicians, global/rural health
practitioners, and veterinarians: customers who need portable equipment to answer quick questions about a patient’s condition to efficiently make diagnoses and decisions about care. The platform is currently being beta tested at Pima Heart and El Rio Health Center in Tucson. VistaScan has been piloted with Saving Mothers to provide 30 effective prenatal exams to rural patients in various stages of pregnancy. VistaScan has also been utilized by Global Emergency Care; first, it was utilized in an emergency to detect evidence of gall stones on a patient, eventually resulting in life-saving treatment being administered. In the second use case, 40 teaching exams were given with VistaScan to 15 emergency medicine clinicians over the course of two weeks.
Market Opportunity: More than 615 million ultrasound scans are done each year around the world. The global ultrasound market is valued at $7 billion and is forecasted to increase to $8.6 billion by 2020. Portable ultrasound, the total available market, is a segment currently valued at over $1 billion. Most of the systems sold in this market segment are portable suitcase-like systems that are heavy, bulky, and expensive ($20,000 and above). There is increasing demand for mobile-device-based technology that is less expensive and more versatile. The growth in handheld ultrasound technology is expected to be more than double that of cart ultrasound machines: 8% (versus 4%) over the next 3 years. Clearly, the future of ultrasound is in the form of portable imaging equipment.
Management Team Courtney Williams, Co-founder & CEO has 12 years of leading customer metrics and analytics in Fortune 500 companies, and international marketing experience in Africa, Latin America, and Asia. She is a Marketing graduate from the University of Arizona Eller College of Management and received her MBA in Global Business from Thunderbird School of Global Management.
Jose Luis Juarez, Co-founder & CTO is the lead technical innovator and has developed new methods to optimize the computational power of mobile devices for medical imaging. Jose is an expert in software architecture and has 12 years of experience leading diagnostic machinery projects at Philips, X-rays and MRI medical equipment for ATOS Siemens and Roche. He has a degree in Software Engineering from UTN, one of the leading software universities in Argentina.
Advisors Anita Bell: Director of Arizona Center for Innovation; has helped grow over 100 technology startups Gregory White: Business expert; served as top financial executive for Fortune 50 aerospace firms Susan Goodman, JD: HIPAA and patient data privacy expert Harvey Maksvytis, MD: Expert trainer for clinicians, Internal Medicine physician with 35 years in practice Bradley Dreifuss, MD: Co-Director of Global Programs, Banner; Emergency Medicine physician Nathan Cristea: Lead sonography trainer at Pima Heart in Tucson Daphne Rosales, MD: Family medicine expert at El Rio Community Health Center in Tucson
Lighthouse247.com
6633 E Greenway Parkway
415.350.6009
LIGHTHOUSE unleashes the power of voice-based patient health programs to transform patient
outcomes and fundamentally change the cost of specific-condition patient populations. We put
your doctor on your kitchen table, and change your life. Every five minutes another eight
Americans die of a heart attack, one loses a limb to diabetes, and another sixty are diagnosed
with a “chronic” condition – our commitment is to drive those numbers to zero.
LIGHTHOUSE is where population health, coordinated care, and health coaching meet, within
the high scale framework of tele-health. By helping populations build core skills in diet, physical
activity, taking their meds and writing stuff down, we bridge the gap between “what my doctor
told me to do” and “how to do it”. Our direct integrations transform EMRs into population
health tools, surfacing gaps in care and between-appointment health priorities, and at the same
time meeting an continuously growing list of Medicare reimbursements in coordinated care and
telehealth. Each morning the patients says “Alexa, check in with LIGHTHOUSE”, and their
doctor designed care plan, overlaid with clinical standards from expert sources, filled out from
our 10,000 item education library and secured for privacy and HIPAA compliance replies with
the two or three priorities to advance their health for the day. Four items drive our competitive
advantage and separate us from other choices: 1. Direct EMR integration powers truly
individualized plans and puts us in the middle of the patient-doctor flow…the only place to
make impact, 2. our “voice AI” creates relationship-building patient experiences that blow away
other digital programs in both usage and NPS, 3. close partnerships with care organizations like
the American Diabetes Association give us unfair expertise, brand recognition and credibility,
and 4. as our per/patient Medicare reimbursement climbs from $45/month to $70/month we
are an easy choice that creates rapid switching costs.
In ten years, 80MM Americans will have at least two chronic conditions, and around the world
every major market is seeing fundamental demographic shifts and skyrocketing health costs.
Under our current business model of Medicare reimbursement, more than $20B is budgeted
annually to support programs we enable, a number which is less than 10% of related insurance
company and health care system costs. We’ve built our proof case in coordinated care with an
initial population of 5,000 patients, and now with tailwind partners including Novo Nordisk,
Johnson and Johnson, the American Diabetes Association and recognition from Allscripts,
athenahealth and Pfizer, our twelve month plan is to engage 25,000 patients representing
patient panels in excess of 500,000. Collective market penetration is below 30%, so it is early
days, and our broad set of ecosystem partners demonstrates that everyone wants programs
like ours to succeed.
At the heart of our voice team is CEO Dave Vockell and Product Lead Kay Custis. Dave’s
enterprise creds reach back to his work on the Yahoo! behavioral ad platform and digital health
to the late 00s building the first SMS program to use real patient data to drive adherence,
building Pfizer’s initial “text adverse event engine”. Kay brings 20 years of health innovation
